This research investigates whether weight loss from the GLP-1 drug semaglutide includes loss of muscle mass. Using an obesity mouse model and direct muscle measurements, the study found significant muscle loss in females but not males. The findings highlight important sex differences and the need to evaluate body composition, not just weight loss.

This research challenges the one-size-fits-all approach to obesity by comparing childhood- and adult-onset cases. Through physiological testing before and after weight loss, it examines differences in inflammation, metabolism, and fitness. Findings aim to support personalised treatments, improving patient outcomes and reducing the broader healthcare burden associated with obesity.